Literature DB >> 9167490

p53 in drug resistance in ovarian cancer.

C Lavarino, D Delia, S Di Palma, F Zunino, S Pilotti.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9167490     DOI: 10.1016/S0140-6736(05)62140-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer.

Authors:  Mirko Marabese; Sergio Marchini; Eleonora Marrazzo; Pietro Mariani; Dario Cattaneo; Roldano Fossati; Anna Compagnoni; Mauro Signorelli; Ute M Moll; A Maria Codegoni; Massimo Broggini
Journal:  Eur J Cancer       Date:  2007-11-26       Impact factor: 9.162

Review 2.  Chemoresistance and targeted therapies in ovarian and endometrial cancers.

Authors:  Kevin Brasseur; Nicolas Gévry; Eric Asselin
Journal:  Oncotarget       Date:  2017-01-17

3.  Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.

Authors:  B Smith-Sørensen; J Kaern; R Holm; A Dørum; C Tropé; A L Børresen-Dale
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

4.  CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.

Authors:  Michael D Oberst; Stacy Fuhrmann; Kathy Mulgrew; Maria Amann; Lily Cheng; Petra Lutterbuese; Laura Richman; Steve Coats; Patrick A Baeuerle; Scott A Hammond
Journal:  MAbs       Date:  2014       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.